BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 52 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $748,132 | -83.2% | 771,000 | -83.0% | 0.00% | -80.0% |
| Q2 2023 | $4,455,753 | -4.0% | 4,530,000 | 0.0% | 0.02% | -6.2% |
| Q1 2023 | $4,643,069 | -4.1% | 4,530,000 | 0.0% | 0.02% | -5.9% |
| Q4 2022 | $4,841,438 | -67.2% | 4,530,000 | -69.5% | 0.02% | -41.4% |
| Q3 2022 | $14,746,161 | +0.3% | 14,860,000 | 0.0% | 0.03% | +7.4% |
| Q2 2022 | $14,707,917 | -13.2% | 14,860,000 | -11.9% | 0.03% | +12.5% |
| Q1 2022 | $16,935,851 | +90.2% | 16,860,000 | +100.0% | 0.02% | +4.3% |
| Q4 2021 | $8,906,000 | -19.0% | 8,430,000 | -20.4% | 0.02% | -25.8% |
| Q3 2021 | $10,997,000 | -50.3% | 10,590,000 | -50.0% | 0.03% | -3.1% |
| Q2 2021 | $22,132,000 | +99.2% | 21,180,000 | +100.0% | 0.03% | -5.9% |
| Q1 2021 | $11,110,000 | -2.1% | 10,590,000 | 0.0% | 0.03% | -5.6% |
| Q4 2020 | $11,354,000 | +28.0% | 10,590,000 | +27.3% | 0.04% | +12.5% |
| Q3 2020 | $8,867,000 | +21.7% | 8,320,000 | +39.6% | 0.03% | +128.6% |
| Q2 2020 | $7,284,000 | – | 5,960,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
| PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
| Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
| SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
| PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
| RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
| KBC Group NV | 400,000 | $40,316,000 | 0.15% |
| PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
| MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |